1.GalièN，Palazzini M，Manes A.Pulmonary arterial hypertension:from the kingdom of the near-dead to multiple clinical trial meta-analyses.Eur Heart J，2010，31（17）:2080-2086.

2.Rabinovitch M.Molecular pathogenesis of pulmonary arterial hypertension.J Clin Invest，2012，122（12）: 4306-4313.

3.GalièN，Hoeper MM，Humbert M，et al.Guidelines for the diagnosis and treatment of pulmonary hypertension:the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology（ESC）and the European Respiratory Society（ERS），endorsed by the International Society of Heart and Lung Transplantation（ISHLT）.Eur Heart J，2009，30（20）:2493-2537.

4.Rich S，Dantzker DR，Ayres SM，et al.Primary pulmonary hypertension.A national prospective study. Ann Intern Med，1987，107（2）:216-223.

5.D′Alonzo GE，Barst RJ，Ayres SM，et al.Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.Ann Intern Med，1991，115（5）:343-349.

6.Humbert M，Sitbon O，Chaouat A，et al.Pulmonary arterial hypertension in France:results from a national registry.Am J Respir Crit Care Med，2006，173（9）:1023-1030.

7.Humbert M，Sitbon O，Yaïci A，et al；French Pulmonary Arterial Hypertension Network.Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension.Eur Respir J，2010，36 （3）:549-555.

8.Humbert M，Sitbon O，Chaouat A，et al.Survival in patients with idiopathic，familial，and anorexigen-associated pulmonary arterial hypertension in the modern management era.Circulation，2010，122（2）:156-163.

9.Frost AE，Badesch DB，Barst RJ，et al.The changing picture of patients with pulmonary arterial hypertension in the United States:how REVEAL differs from historic and non-US Contemporary Registries. Chest，2011，139（1）:128-137.

10.Benza RL，Miller DP，Barst RJ，et al.An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry.Chest，2012，142（2）:448-456.

11.Escribano-Subias P，Blanco I，López-Meseguer M，et al；REHAP investigators.Survival in pulmonary hypertension in Spain:insights from the Spanish registry.Eur Respir J，2012，40（3）:596-603.

12.Ling Y，Johnson MK，Kiely DG，et al.Changing demographics，epidemiology，and survival of incident pulmonary arterial hypertension:results from the pulmonary hypertension registry of the United Kingdom and Ireland.Am J Respir Crit Care Med，2012，186（8）:790-796.

13.Hoeper MM，Huscher D，Ghofrani HA，et al.Elderly patients diagnosed with idiopathic pulmonary arterial hypertension:Results from the COMPERA registry.Int J Cardiol，2012，168（2）:871-880.

14.Machado RD，Eickelberg O，Elliott CG，et al.Genetics and genomics of pulmonary arterial hypertension.J Am Coll Cardiol，2009，54（1suppl）:S32-S42.

15.Rosenzweig EB，Morse JH，Knowles JA，et al.Clinical implications of determining BMPR2mutation status in a large cohort of children and adults with pulmonary arterial hypertension.J Heart Lung Transplant，2008，27（6）:668-674.

16.Ma L，Roman-Campos D，Austin ED，et al.A novel channelopathy in pulmonary arterial hypertension.N Engl J Med，2013，369（4）:351-361.

17.Mathai SC，Hassoun PM.Pulmonary arterial hypertension in connective tissue diseases.Heart Fail Clin，2012，8（3）:413-425.

18.Jiang X，Humbert M，Jing ZC.Idiopathic pulmonary arterial hypertension and its prognosis in the modern management era in developed and developing countries.In:Humbert M，Souza R，Simonneau G，eds.Pulmonary Vascular Disorders.Prog Respir Res.Basel:Karger，2012:85-93.

19.Lowe BS，Therrien J，Ionescu-Ittu R，et al.Diagnosis of pulmonary hypertension in the congenital heart disease adult population impact on outcomes.J Am Coll Cardiol，2011，58（5）:538-546.

20.Sitbon O，Lascoux-Combe C，Delfraissy JF，et al.Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era.Am J Respir Crit Care Med，2008，177（1）:108-113.

21.Opravil M，Sereni D:Natural history of HIV-associated pulmonary arterial hypertension:trends in the HAART era.AIDS，2008，22（suppl 3）:S35-S40.

22.Opravil M，Pechere M，Speich R，et al.Natural history of HIV-associated pulmonary arterial hypertension:trends in the HAART era.Am J Respir Crit Care Med，1997，155（3）:990-995.

23.Degano B，Guillaume M，Savale L，et al.HIV-associated pulmonary arterial hypertension:survival and prognostic factors in the modern therapeutic era.AIDS，2010，24（1）:67-75.

24.Hadengue A，Benhayoun MK，Lebrec D，et al.Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics.Gastroenterology，1991，100（2）:520-528.

25.Le Pavec J，Souza R，Herve P，et al.Portopulmonary hypertension:survival and prognostic factors.Am J Respir Crit Care Med，2008，178（6）:637-643.

26.Rich S，Rubin L，Walker AM，et al.Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension.Chest，2000，117（3）:870-874.

27.Montani D，Bergot E，Günther S，et al.Pulmonary arterial hypertension in patients treated by dasatinib. Circulation，2012，125（17）:2128-2137.

28.Lapa M DB，Jardim C，Fernandes CJ，et al.Cardiopulmonary manifestations of hepatosplenic schistosomiasis.Circulation，2009，119（11）:1518-1523.

29.dos Santos Fernandes CJ，Jardim CV，Hovnanian A，et al.Survival in schistosomiasis-associated pulmonary arterial hypertension.J Am Coll Cardiol，2010，56（9）:715-720.

30.Montani D，Price LC，Dorfmuller P，et al.Pulmonary veno-occlusive disease.Eur Respir J，2009，33（1）: 189-200.

31.Jing ZC，Xu XQ，Han ZY，et al.Registry and survival study in chinese patients with idiopathic and familial pulmonary arterial hypertension.Chest，2007，132（2）:373-379.